Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP the PLRG report

Autor: Beata Kumiega, Katarzyna Kobylińska, Agnieszka Giza, Monika Długosz-Danecka, Wojciech Spychałowicz, Joanna Drozd-Sokołowska, Wanda Knopinska-Posluszny, Sebastian Giebel, Wieslaw Wiktor-Jedrzejczak, Joanna Fischer, Przemyslaw Biecek, Tomasz Wróbel, Jan Maciej Zaucha, Joanna Romejko-Jarosinska, Wojciech Jurczak, Monika Joks
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Adult
Male
medicine.medical_specialty
Adolescent
lcsh:Medicine
030204 cardiovascular system & hematology
Gastroenterology
Article
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
International Prognostic Index
hemic and lymphatic diseases
Internal medicine
Diabetes mellitus
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Progression-free survival
lcsh:Science
Cyclophosphamide
Survival rate
Aged
Aged
80 and over
Multidisciplinary
B-cell lymphoma
business.industry
Incidence (epidemiology)
lcsh:R
Type 2 Diabetes Mellitus
Type 2 diabetes
Middle Aged
medicine.disease
Lymphoma
Survival Rate
Diabetes Mellitus
Type 2
Doxorubicin
Vincristine
030220 oncology & carcinogenesis
Prednisone
Female
lcsh:Q
Lymphoma
Large B-Cell
Diffuse
Rituximab
business
Diffuse large B-cell lymphoma
Follow-Up Studies
Zdroj: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Popis: Comorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus (DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized that pre-existing DMT2 may negatively affect the outcome of DLBCL. To verify this, DLBCL patients treated with (R)-CHOP were enrolled. 469 patients were eligible, with a median age of 57 years; 356 patients had advanced-stage DLBCL. 126 patients had high-intermediate and 83 high-risk international prognostic index (IPI). Seventy-six patients had DMT2, 46 HF; 26 patients suffered from both DMT2 and HF. In the analyzed group DMT2 or HF significantly shortened overall survival (OS) and progression free survival (PFS): the 5-year OS for patients with DMT2 was 64% vs 79% and for those with HF: 49% vs 79%. The 5-year PFS for DMT2 was 50.6% vs 62.5% and for HF 39.4% vs 63.2%. The relapse/progression incidence was comparable between groups; the non-relapse/progression mortality (NRPM) was significantly higher solely in DMT2 patients (5-year NRPM 22.5% vs 8.4%). The risk of death was higher in patients with higher IPI (HR = 1.85) and with DMT2 (HR = 1.87). To conclude, pre-existing DMT2, in addition to a higher IPI and HF, was a negative predictor for OS and PFS.
Databáze: OpenAIRE
Externí odkaz: